Neuroscience & CNS
Part of Biotech - Drug Development
 BIIB | Biogen Inc. Common Stock | $32.9b | $217.05 | +0.4% | 109.7K |
 NBIX | Neurocrine Biosciences Inc | $16.1b | $150.34 | +0.3% | 211.7K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $15.9b | $242.24 | +0.6% | 124.9K |
 AXSM | Axsome Therapeutics, Inc | $11.0b | $213.67 | +3.8% | 283.7K |
 CYTK | Cytokinetics Inc. | $10.0b | $69.90 | +0.6% | 194.9K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $9.9b | $311.25 | +0.0% | 166.1K |
 TGTX | TG Therapeutics, Inc. | $8.7b | $55.33 | +5.1% | 864.9K |
 ALKS | Alkermes Inc. plc | $8.0b | $46.09 | +0.1% | 313.1K |
 PTCT | PTC Therapeutics, Inc. | $6.0b | $67.66 | +2.5% | 482.9K |
 XENE | Xenon Pharmaceuticals Inc | $5.8b | $57.16 | +1.9% | 145.5K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $5.2b | $38.03 | +2.5% | 377.9K |
 ACAD | Acadia Pharmaceuticals Inc. | $5.0b | $27.22 | +1.5% | 157.5K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.1b | $33.98 | -0.9% | 346.9K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $3.8b | $32.72 | -1.4% | 473.2K |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.7b | $20.24 | -0.8% | 383.2K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $3.2b | $5.68 | 0.0% | 32.9K |
 ATAI | AtaiBeckley Inc. Common Stock | $2.7b | $7.33 | 0.0% | N/A |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.6b | $40.91 | -0.8% | 111.8K |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $2.5b | $42.64 | +1.1% | 214.2K |
 BHVN | Biohaven Ltd. | $2.4b | $12.20 | -0.9% | 208.9K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $2.3b | $42.69 | +0.3% | 52.2K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.9b | $27.98 | -0.4% | 58.6K |
 GHRS | GH Research PLC Ordinary Shares | $1.9b | $27.46 | -0.1% | 26.2K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.8b | $5.05 | -0.3% | 458.3K |
 LBRX | LB Pharmaceuticals Inc Common Stock | $1.6b | $43.15 | +0.7% | 38.0K |
 ANRO | Alto Neuroscience Inc. | $1.4b | $30.80 | +1.7% | 87.1K |
 ALMS | Alumis Inc. Common Stock | $1.3b | $8.00 | -3.5% | 986.4K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $3.96 | +0.9% | 821.2K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $17.04 | -0.1% | 47.7K |
 HELP | Cybin Inc. Common Stock | $0.9b | $13.65 | +3.5% | 248.4K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $0.8b | $21.74 | -0.2% | 182.0K |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.7b | $60.12 | -0.1% | 19.7K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.7b | $4.93 | +2.2% | 337.6K |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.6b | $14.37 | +2.4% | 89.0K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $0.6b | $11.85 | -1.5% | 46.7K |
 OVID | Ovid Therapeutics Inc. Common Stock | $0.5b | $2.75 | +1.3% | 246.6K |
 PRTA | Prothena Corporation plc Ordinary Shares | $492.8m | $8.26 | -0.8% | 70.9K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $466.1m | $4.33 | -2.8% | 220.4K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $348.8m | $2.33 | 0.0% | 68.9K |
 VNDA | Vanda Pharmaceuticals Inc. | $322.9m | $4.99 | -0.2% | 76.4K |
 ALEC | Alector, Inc. Common Stock | $303.7m | $1.99 | -1.7% | 78.8K |
 ACIU | AC Immune SA | $282.4m | $2.71 | +1.3% | 49.6K |
 AVXL | Anavex Life Sciences | $267.9m | $2.42 | -0.4% | 210.2K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $253.7m | $0.82 | +0.2% | 1.6M |
 NGEN | NervGen Pharma Corp. Common stock | $249.5m | $2.17 | +0.9% | 50.6K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $243.0m | $2.68 | -1.7% | 154.9K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $229.3m | $11.79 | +1.2% | 43.2K |
 ABOS | Acumen Pharmaceuticals, Inc. Common Stock | $224.2m | $2.86 | -0.7% | 87.0K |
 NERV | Minerva Neurosciences, Inc | $223.9m | $3.67 | -3.9% | 43.1K |
 PEPG | PepGen Inc. Common Stock | $220.2m | $2.92 | +1.2% | 176.9K |